Prognosis and possibilities of treatment of inaugural metastases;Pronostic et possibilités thérapeutiques des métastases inaugurales

Presse Medicale

Volumn 32, Issue 21, 2003, Pages 997-1003

  Penel, Nicolas ^a  

^a CENTRE OSCAR LAMBRET   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; LACTATE DEHYDROGENASE; METHOTREXATE; MITOMYCIN; PACLITAXEL; TAMOXIFEN; VINBLASTINE; VINCRISTINE; VINDESINE;

ADULT; AGED; AXILLARY LYMPH NODE; CANCER ADJUVANT THERAPY; CARCINOMA; CARCINOMA OF UNKNOWN PRIMARY SITE; CERVICAL LYMPH NODE; CLINICAL FEATURE; GERM CELL TUMOR; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MEDIAN LINE SYNDROME; METASTASIS; MULTIMODALITY CANCER THERAPY; OVARY CANCER; PERITONEAL SEROUS PAPILLARY CARCINOMATOSIS; PROGNOSIS; REVIEW; SQUAMOUS CELL CARCINOMA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; PROGNOSIS;

EID: 0037599514     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Lortholary E, Abadie-Lacourtoisie S, Guerin O, Mege M, Rauglaudre GD, Gamelin E. Cancers of unknown origin: 311 cases. Bull Cancer 2001; 88: 619-27.
2. Muir C. Cancer of unknown primary site. Cancer 1995; 75: 353-6.
3. Van der Gaast A, Verweij J, Plantings AS, Hop WC, Stoter G. Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site. J Clin Oncol 1995; 13: 1720-5.
4. Oen AL, De Boer MF, Hop WC, Kneght P. Cervical metastasis from the unknown primary tumor. Eur Arch Otolaryngol 1995; 252: 222-8.
5. Bugat R, Bataillard A, Lesimple T et al. Standard, Options et recommandations 2002 pour la prise en charge des patients atteints de carcinomes de site primitif inconnu (rapport abrégé). Bull Cancer 2002; 89: 869-75.
6. Weber A, Schmoz S, Bootz F. CUP (carcinoma of unknown primary) syndrome in head and neck: clinic, diagnostic, and therapy. Onkologie 2001; 24: 38-43.
7. Jakobsen J, Aschenfeldt P, Johansen J, Jorgensen K. Lymph node metastases in neck from unknown primary tumour. Acta Oncol 1992; 635-55.
8. Medini E, Medini AM, Lee CK, Gapany M, Levitt SH. The management of metastatic squamous cell carcinoma in cervical lymph nodes from an unknown primary. Am J Clin Oncol 1998; 21: 121-5
9. Lefebvre JL, Adenis L, Coche-Dequant B, Depadt G, Buisset E. Cervical adenopathies of unknown primary site. A propos of 190 cases. Ann Otolaryngol Clin Cervicofac 1987; 10: 513-18.
10. Erkal HS, Mendenhall WM, Amdur RJ, Villaret DB, Stringer SP. Squamous cell carcinomas metastatic to cervical lymph node from an unknown head and neck mucosal treated with radiation therapy with palliative intent. Radiother 2001; 59: 319-21.
11. McMahon J, Hruby G, O'Brien CJ et al. Neck dissection and ipsilateral radiotherapy in the management of cervical metastatic carcinoma from an unknown primary. Aust N Z Surg 2000; 70: 263-8.
12. De Braud F, Al-Sarraf M. Diagnosis and mangement of squamous cell carcinoma of unknown primary site of the neck. Semin Oncol 1993; 20: 273-8.
13. Eschwege F, de Gueddari B, Boukhis J. Carcinoma of the nasopharynx. Clinical aspects, indication and results of esternal radiotherapy and brachytherapy. State of the art in 2001. Cancer Radiother 2001; 5: S1189-S194.
14. Ellebroek N. Treatment of patients with isolated axillary metastases without evidence of primary carcinoma consistent with breast origin. Cancer 1990; 66: 1461
15. Merson M, Andeola S, Galimbertir V, Bufalino R, Marchini S, Veronesi U. Breast carcinoma presenting as axillary nodal metastases without evidence of primary tumour. Cancer 1992; 70: 504-8.
16. Foroudi F, Tiver KW. Occult breast carcinoma presenting as axillary metastases. Int J Radiat Oncol Biol Phys 2000; 47: 143-7.
17. Jackson B, Scott-Conner C, Moulder J. Axillary metastasis from occult breast carcinoma: diagnosis management. Am Surg 1995; 61: 431-4
18. Van Ooijen B, Bontendbal M, Henzen-Logmans SC, Kooper PC. Axillary nodal metastases from an occult primary consistent breast cancer. Br J Surg 1993; 80: 1299-300.
19. Fowler JM, Nieberg RK, Schooler TA, Berek JS. Peritoneal adenocarcinoma (serous) of Mullerian type: a subgroup of women presenting with peritoneal carcinomatous. Int J Gynecol Cancer 1994; 4: 43-51.
20. Fromh GL, Gershenson DH, Da Silva EG. Papillary serous carcinoma of the peritoneum. Obstret Gynecol 1990; 75: 89-95.
21. Yann LT, Winckler CF, Janckila AJ, Li CY, Lam KW. Prostatic cancer presenting as metastatic adenocarcinoma of undetermined origin. Cancer 1993; 51: 283-7.
22. Greco FA, Vangman WY, Hainsworth JD. Advanced poorly differentiated carcinoma of unknown primary site: recognition of a treatable syndrome. Ann Int Med 1996; 104: 547-53.
23. Currow DC, Findlay M, Cox K, Harnett PR. Elevated germ cell markers in carcinoma of uncertain primary do not predict response to platinum based chemotherapy. Eur J Cancer 1996; 32A: 2357-9.
24. Culine S, Gazagne L, Ychou M. et al. Carcinoma of unknown primary site. A propos of 100 patients treated at the Montpellier regional center of cancer. Rev Med Interne 1998; 19: 713-19.
25. Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol 1995; 13: 2094-2103.
26. Culine S, Kramar A, Saghatchian M. et al. Develoment and validation of a prognostic moel to predict lenght of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 2002; 20: 4679-83.
27. Briasoulis E, Tsokos M, Fountzila G et al. Bcl2 and p53 protein expression in metastatic carcinoma of unknown origin: biological and clinical implication. Hellenic Co-operative Oncology Group Study. Anticancer Res 1998; 18: 1907-14.
28. Falkson CI, Cohen GL. Mitomycin, epirubicin and cisplatin versus mitomycin C: as therapy for carcinoma of unknown primary origin. Oncology 1998; 55: 116-21.
29. Farrugia Dc, Norman AR, Nicolson MC et al. Unknown primary carcinoma: randomised studies are needed to identify otimal treaments and their benefits. Eur J Cancer 1996; 32A: 2256-61.
30. Moertel CG, Reitmeier RJ, Schutt AJ, Hahn RG. Treatment of patient with adenocarcinoma of unknown origin. Cancer 1972; 30: 1469-72.
31. Schildt RA, Kennedy PS, Chen TT, Athens JW, O'Bryan RM, Balcerzak SP. Management of patients with metastatic adenocarcinoma of unknown origin. A Southwest Oncology Group Study. Cancer Treat Rep 1983; 67: 77-9.
32. Nole F, Colleoni M, Buzzoni R, Barjetta E. Fluorouracil plus acid folinic in metastatic adenocarcinoma of unknown primary site suggested of a gastric intestinal primary. Tumori 1993; 79: 116-18.
33. Walach N, Horn Y. Combination chemotherapy in the treatment of adenocarcinoma of unknown primary origin. Cancer Treat Rep 1987; 71: 605-7.
34. Milliken ST, Tattersal MH, Woods RL et al. Metastatic adenocarcinoma of unknown primary site. A randomized study of two combination chemotherapy regimen. Eur J Cancer Clin Oncol 1987; 23: 1645-8.
35. Goldberg RM, Smith FP, Ueno W, Ahlgren JD, Schein PS. 5-fluoro-uracil, adriamycin, and mitomycin in the treatment of adenocarcinoma of unknown primary. J Clin Oncol 1986; 4: 395-9.
36. Van Der Gaast A, Erweil J, Planting AS, Stoter G. 5-fluoro-uracil, doxorubicin and mitomycin C (FAM) combination chemotherapy for metastatic adenocarcinoma of unknown primary. Eur J Cancer Clin Oncol 1988; 24: 765-8.
37. Al-Idrissi HY. Combined 5-fluoro-uracil, adriamycin and mitomycin C in the management of adenocarcinoma metastasizing to the liver from an unknown primary site. J Int Med Res 1990; 18: 425-9.
38. Treat J, Falchick SC, Tremblay C et al. Phase II trial of methotrexate-FAM (m-FAM) in adenocarcinoma of unknown primary. Eur J Cancer Clin Oncol 1989; 25: 1053-5.
39. Fiore JJ, Kelsen DP, Gralla RJ et al. Adenocarcinoma of unknown primary origin: treatment with vindesine and doxorubicin. Cancer Treat Rep 1985; 69: 591-4.
40. Anderson H, Thatcher N, Rankin E, Wagstaff J, Scarffe JH, Crowther D. VAC (Vincristin, adriamycin, cyclophosphamide) chemotherapy for metastatic carcinoma of unknown primary site. Eur J Cancer Clin Oncol 1983; 19: 49-52.
41. Wagener DJ, De Mulder PH, Burghouts JT, Croles JJ. Phase II of cisplatin for adenocarcinoma of unknown primary site IKZ/IKO Clinical Research Group. Eur J Cancer 1991; 27: 755-7.
42. Guardiola E, Pivot X, Tchicknavorian X et al. Combination of cisplatin-doxorubicin-cyclophosphamide in adenocarcinoma of unknown primary site: a phase II trial. Am J Clin Oncol 2001; 24: 372-5.
43. Bedikina AY, Bodey GP, Valdivieso M, Burgess MA. Sequential chemotherapy for adenocarcinoma of unknown primary. Am J Clin Oncol 1983; 6: 219-24.
44. Pasterz R, Savaraj N, Burgess M. Prognostic factors in metastatic carcinoma of unknown primary. J Clin Oncol 1986; 1652-7.
45. Hainsworth JD, Johnson DH, Greco FA. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated adenocarcinoma of unknown primary: results of a 12-years experience. J Clin Oncol 1992; 10: 912-22.
46. Voog E, Merrouche Y, Trillet-Lenoir V et al. Multicentric phase II study of cisplatin and etoposide in patients with metastatic carcinoma of unknown primary. Am J Clin Oncol 2000; 23: 614-16.
47. Raber MN, Faintuch J, Abbruzzese JL, Sumrall C, Frost P. Continuous infusion 5-fluorouracil, etoposide and cisdiamminedichloroplatinum in patients with metastatic carcinoma of unknown origin. Ann Oncol 1991; 2: 519-20.
48. Karapetis CS, Yip D, Virik K et al. Epirubicin, cisplatin, and prolonged or brief infusionnal 5-fluoruracil in the treatment of carcinoma of unknown primary site. Med Oncol 2001; 18: 23-32.
49. Culine S, Fabbro M, Ychou M, Romieu G, Cupissol D, Pinguet F. Alternative bimonthly cycles of doxorubicin, cyclophosphamide and etoposide, cisplatin with hematopoietic growth factor support in patients with carcinoma of unknown primary site. Cancer 2002; 94: 840-6.
50. Lofts FJ, Gogas H, Mansi JL. Management of adenocarcinoma of unknown primary with 5-fluoro-uracil-cisplatin chemotherapy regimen (CFTam). Ann Oncol 1999; 13: 89-92.
51. Warner E, Goel R, Chang J et al. A multicenter phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site. Br J Cancer 1998; 77: 2376-80.
52. Dowell JE, Garrett AM, Shyr Y, Johnson DH, Hande KR. A randomized phase II trial in patients with carcinoma of unknown primary site. Cancer 2001; 91: 592-7.
53. Van Der Gaast A, Henzen-Logmans SC, Planting AS, Stoter G, Verweij J. Phase II study of oral administration of etoposide for patients with well-and moderately-differentiated adenocarcinoma of unknown primary site. Ann Oncol 1993; 4: 789-90.
54. Hainsworth JD, Erland JB, Kalman LA, Schreeder MT, Greco FA. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. J Clin Oncol 1997; 16: 2385-93.
55. Briasoulis E, Koulofonos H, Bafaloukos D et al. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. J Clin Oncol 2000; 18: 3101-7
56. Dowell JE, Garrett AM, Shyr Y, Johnson DH, Hande KR. A randomized phase II trial in patients with carcinoma of an unknown primary site. Cancer 2001; 91: 592-7
57. Greco FA, Erland JB, Morissey LH et al. Carcinoma of unknown primary site: phase II trial with docetaxel plus cisplatin or carboplatin. Ann Oncol 2000; 11: 211-15.
58. Greco FA, Burris HA 3rd, Litchy S et al. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. J Clin Oncol 2002; 20: 1651-6.
59. Hainsworth JD, Burris HA 3rd, Calvert SW et al. Gemcitabine in the second-ligne therapy of patients with carcinoma of unknown primary site: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer Invest 2001; 19: 335-9.
60. Culine S, Ychou M, Fabbro M, Romieu G, Cupissol D. 5-fluorouracil and leucovorin as second-line chemotherapy carcinomas of unknown primary site. Anticancer Res 2001; 21: 1455-7.
61. Van de Vouw AJ, Janssen-Heijnen MLG, Coebergh JWW, Hillen HFF. Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992. Eur J Cancer 2002; 38: 409-13.
62. Hales SA, Gatter KC, Hereyt A, Mason DY. Value of immunocytochemistry in differentiating hight-grade lymphoma from the other anaplastic tumours. A study of anaplastic tumours from 1940 to 1960. Leuk Lymphoma 1989; 1: 59.
63. Kirshbom PM, Kherani AR, Onakis MW, Feldman JM, Tyler DS. Carcinoids of unknown origin: comparative analysis with foregut, midgut and hindgut carcinoids. Surgery 1998; 124: 1063-70.
64. Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuro-endocrine carcinomas with combined etoposide and cisplatine. Cancer 1991; 68: 227-32.
65. Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE, Scmitz PI. Identification of pronostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 1999; 43: 795-803.
66. Ruda R, Borgognone M, Benech F, Vasario E, Soffietti R. Brain metastases from unknown primary tumour; a prospective study. J Neurol 2001; 248: 394-8.
67. Delarive J, de Tribolet N. Cerebral metastases. A study of a surgical series of 81 cases. Neurochirurgie 1992; 38: 89-97
68. Vialat JR, Boutin C. Malignant pleural effusions: recourse to early use of talc. Rev Med Interne 1998; 19: 811-18.
69. Ang P, Tan EH, Leong SS, Koh L, Eng P, Agasthian T, Cheah FK. Primary intrathoracic malignant effusion: a descriptive study. Chest 2001; 120: 50-4.
70. Ayoub JP, Hess JR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL. Unknown primary tumors metastatic to liver. J Clin Oncol 1998; 16; 2105-12.
71. Elias D, Cavalcanti de Albuquerque A, Eggenspieler P et al. Resection of liver metastases from a noncolorectal primary: indications and results based on 147 monocentric patients. J Am Coll Surg 1998; 187: 487-93.
72. Cancer secondaire des os. Eds Bontoux D, Alcalay M. Expansion Scientifique Française, 1997, Paris.
73. Hainsworth JD, Lennington WJ, Greco FA. Overexpression of Her-2 in patients with poorly differentiated carcinoma of poorly differentiated adenocarcinoma of unknown primary site. J Clin Oncol 2000; 18: 632-5.